Oncology Diagnostics Panel Session
As the oncology landscape continues to grow and develop, the diagnostics developed and used will need to keep pace with the therapeutics. To help us understand exactly what it will take to do so, Kineticos recently hosted a panel with 3 industry veterans to gain insight regarding the nuances of the oncology diagnostics market.
- Eric Mayer, CEO, EDP Biotech
- Sandra Dunn, CEO, Phoenix Molecular
- Brian Kelly, Global Director, Diagnostic Partnering, Thermo Fisher
Click here for a condensed and edited version of Part 1.
Subscribe to Kineticos to receive weekly emails containing insightful content.